21 CFR 522.1850
§ 522.1850 Polysulfated glycosaminoglycan.
United States · 21 CFR — Food and Drugs · Status: effective
Cite this
- Citation
- 21 CFR 522.1850, § 522.1850 Polysulfated glycosaminoglycan, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/87513
- Permanent ID
ys:prov:87513@1- SHA-256
c8a7772b66228ec95b71f973b889d10bdcb69dea45b173aea4f4c5f65e9fa73a
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) Specifications.
(1) Each 1-milliliter (mL) ampule of solution contains 250 milligrams (mg) polysulfated glycosaminoglycan.
(2) Each mL of solution packaged in 5-mL ampules or 20-, 30-, or 50-mL vials contains 100 mg polysulfated glycosaminoglycan.
(b) Sponsor. See No. 010797 in § 510.600(c) of this chapter.
(c) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(d) Conditions of use—(1) Horses—(i) Indications for use. For the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
(ii) Amount—(A) Intra-articular use (carpal): 250 mg once a week for 5 weeks.
(B) Intramuscular use (carpal and hock): 500 mg every 4 days for 28 days.
(iii) Limitations. Do not use in horses intended for human consumption.
(2) Dogs—(i) Indications for use. For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.
(ii) Amount. 2 mg per pound of body weight by intramuscular injection twice weekly for up to 4 weeks (maximum of 8 injections).
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.